Rituxan targeting good B-cells better?

[Guest guest]

A study from China has looked at CD20 on normal and

malignant B-cells.

They found that the protein was denser and more uniformly

distributed on 'good' B cells

In contrast, CD20 was less dense and not uniform on

malignant CLL B-cells...

Although the study only suggest this, perhaps Rituxan and

other CD20 monoclonals target 'good' B-cells better than the

malignant ones...

http://www.ncbi.nlm.nih.gov/pubmed/21553499?dopt=Abstract

or

http://tinyurl.com/44ffte9